ASCO Endorses ASTRO Guidelines for Endometrial Cancer
(HealthDay News) — The American Society of Clinical Oncology (ASCO) has endorsed postoperative radiation therapy guidelines for endometrial cancer, according to a report published online July 6 in the Journal of Clinical Oncology.
Larissa A. Meyer, MD, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues reviewed the American Society for Radiation Oncology (ASTRO) guideline content and recommendations.
The authors note that the ASTRO recommendations are clear, thorough, and based on the most relevant evidence. For women without residual disease in the hysterectomy specimen, and for women with grade 1 or 2 cancer and <50% myometrial invasion, especially in the absence of other high-risk features, surveillance without adjuvant radiation therapy is reasonable. Vaginal brachytherapy is as effective as pelvic radiation therapy for prevention of vaginal recurrence, and is preferred for women with grade 1 or 2 cancer and ≥50% myometrial invasion or grade 3 cancer and <50% myometrial invasion. Pelvic radiation may be beneficial for preventing recurrence in women with grade 3 cancer and ≥50% myometrial invasion or cervical stroma invasion. Qualifying statements were added to the ASTRO recommendations to provide stronger statements in favor of chemotherapy for women with high-risk early-stage and advanced disease.
"ASCO endorses 'The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline' by Klopp et al, published in 2014 in Practical Radiation Oncology, with qualifying statements," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.